Improving care for adults with Fabry's disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study is looking at how to improve the care and follow-up for people with Fabry's disease, a rare genetic disorder. It aims to create a better care pathway to help patients manage their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have a confirmed diagnosis of Fabry's disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how Fabry disease affects daily life in adults who haven't started treatment yet. Researchers want to understand your experiences and challenges to improve care for people with this rare genetic condition.
This study looks at the quality of life of people aged 65 and older with Fabry disease. It includes patients who are receiving specific treatment and those who are not, to compare their experiences.
This study tests a structured exercise program designed to improve fitness in people with Fabry disease. It aims to see whether regular exercise is a safe and helpful way to support your health.
This study looks at how the heart is affected in adults with Fabry disease. It may help doctors better understand heart-related changes in order to guide care.
This study is a national registry that collects health and medical information from people with Fabry disease. It helps researchers better understand the condition and plan future care and studies.
This study tests an enzyme replacement therapy (agalsidase alfa) for Fabry disease in Chinese children and adults. It's an observational study that follows patients who receive the treatment as part of their regular care.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.